{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Entinostat", "query": { "intervention": "Entinostat" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 61, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Entinostat&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:46:29.771Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00750698", "title": "A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2008-08", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 5, "location_summary": "San Diego, California • Miami, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750698" }, { "nct_id": "NCT03473639", "title": "A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2019-01-29", "completion_date": "2022-11-01", "has_results": false, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 2, "location_summary": "Rochester, New York • Charlottesville, Virginia", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03473639" }, { "nct_id": "NCT02437136", "title": "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Melanoma", "Mismatch Repair-Proficient Colorectal Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2015-08-26", "completion_date": "2022-09-29", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Baltimore, Maryland + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437136" }, { "nct_id": "NCT03552380", "title": "Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roberto Pili", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-07-31", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552380" }, { "nct_id": "NCT01434303", "title": "Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2/Neu Positive", "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-01-10", "completion_date": "2016-02-16", "has_results": false, "last_update_posted_date": "2019-05-20", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01434303" }, { "nct_id": "NCT03179930", "title": "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Relapsed", "Refractory" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-06-07", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 9, "location_summary": "Evanston, Illinois • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179930" }, { "nct_id": "NCT02922933", "title": "A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Volunteers", "Healthy Volunteers", "Human Volunteers", "Normal Volunteers" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "Omeprazole", "type": "DIETARY_SUPPLEMENT" }, { "name": "Famotidine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2016-10-25", "completion_date": "2017-05-08", "has_results": false, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 2, "location_summary": "Tempe, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02922933" }, { "nct_id": "NCT05898828", "title": "Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Esophageal Neoplasms", "Esophagus Neoplasm", "Esophagus Cancer", "Neoplasms, Esophageal", "Esophageal Cancer (EsC)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Montanide(R) ISA-51 VG Adjuvant", "type": "BIOLOGICAL" }, { "name": "H1299 Cell Lysates", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2024-08-02", "completion_date": "2024-08-02", "has_results": false, "last_update_posted_date": "2024-08-05", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05898828" }, { "nct_id": "NCT02915523", "title": "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "avelumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 140, "start_date": "2016-12-19", "completion_date": "2021-04-21", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 12, "location_summary": "Tampa, Florida • West Palm Beach, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915523" }, { "nct_id": "NCT00015925", "title": "MS-275 in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-10", "last_synced_at": "2026-09-02T20:46:29.771Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015925" } ] }